This site is intended for healthcare professionals

CHMP recommends change to authorisation for Vimpat in partial-onset seizures.- UCB

Read time: 1 mins
Published:29th Jan 2022
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Vimpat (lacosamide) from UCB.

The CHMP adopted an extension to an existing indication as follows: Lacosamide UCB is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.

Condition: Epilepsy
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.